Frequently Asked Questions about Replimune Group, Inc. (REPL)

Name: Replimune Group, Inc. (REPL) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Replimune Group, Inc. (REPL) do?

Accepted Answer

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP...

Question 2

Is Replimune Group, Inc. (REPL) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of REPL reveals an Altman Z-Score of -3.85 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if REPL fits their risk profile.

Question 3

What is the current P/E ratio for REPL?

Accepted Answer

As of the latest trading session, Replimune Group, Inc. (REPL) has a trailing P/E ratio of -2.31.

Question 4

Who is the CEO of Replimune Group, Inc.?

Accepted Answer

The current Chief Executive Officer of Replimune Group, Inc. is Sushil Patel.

Question 5

What was REPL's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Replimune Group, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does REPL pay a dividend?

Accepted Answer

Replimune Group, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does REPL have?

Accepted Answer

In its latest reporting period, Replimune Group, Inc. generated $-0.20B in Free Cash Flow against a total debt load of $0.08B.

Question 8

What is the Price-to-Book (P/B) ratio of Replimune Group, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Replimune Group, Inc. (REPL) is currently 3.46.

Question 9

What is the Price-to-Sales (P/S) ratio of REPL?

Accepted Answer

Based on trailing twelve-month data, Replimune Group, Inc. (REPL) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Replimune Group, Inc.'s Return on Equity (ROE)?

Accepted Answer

Replimune Group, Inc. (REPL) has a Return on Equity (ROE) of -102.69%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-03	-192.3M	35M	-6.7M	-198.9M	-234M
2024-03	-185.5M	34.1M	-5.7M	-191.1M	-225.3M
2023-03	-128.1M	28.1M	-2.3M	-130.3M	-158.5M
2022-03	-82.2M	24.3M	-2.3M	-84.5M	-108.8M
2021-03	-61.4M	11.8M	-2.4M	-63.8M	-75.6M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-03	-192.3M	35M	-6.7M	-198.9M	-234M
2024-03	-185.5M	34.1M	-5.7M	-191.1M	-225.3M
2023-03	-128.1M	28.1M	-2.3M	-130.3M	-158.5M
2022-03	-82.2M	24.3M	-2.3M	-84.5M	-108.8M
2021-03	-61.4M	11.8M	-2.4M	-63.8M	-75.6M